Risk-Based Approaches
Risk-based approaches are everyone’s top priority in clinical trials, but no one seems to have a clear playbook.
TRI at Scope Europe 2025
TRI CEO Duncan Hall will be at Scope Europe 2025, sharing how technology is meeting the evolving needs of RBQM.
Is ICH E6(R3) Stalling?
Despite high awareness, ICH E6(R3) adoption is stalling, only 19% of organizations report significant change.
Why Early Alignment on Risk Tolerance Is Critical for Clinical Trials
Early alignment on risk tolerance is essential to ensure efficient, compliant trial execution.
TRI Fest: Where Remote Becomes Remarkable
TRI Fest 2025 brought our team together for a day of collaboration and a bit of friendly chaos.
World Patient Safety Day 2025
This World Patient Safety Day, we’re shining a light on how healthcare professionals can build safety into every interaction.
ICH E6 (R3) and Risk-Based Quality Management
This webinar unpacked the major shifts in ICH E6 (R3), showing how teams can embrace RBQM.
ICH E6 (R3) Is Here, But Only 19% Are Ready
ICH E6 (R3) is here, but only 19% of the industry is ready. While awareness is high, meaningful action is lagging.
Powering a Risk-Based Approach to Clinical Trials
TRI is proud to join the Veeva R&D Summit as a Product Partner, showcasing our collaboration.
5 Mistakes That Could Compromise Your Clinical Trial
Explore five common mistakes that can derail your clinical trial and how OPRA helps teams manage risk.